Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria-Reference-Cited by-同舟云学术

Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria

Published:2018-12-21 Issue:3 Volume:22 Page:226-237
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Walter Evelyn¹,Berger Thomas²,Bajer-Kornek Barbara³,Deisenhammer Florian⁴

Affiliation:

1. IPF Institute for Pharmaeconomic Research, Vienna, Austria;

2. Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria;

3. Medical University of Vienna, Vienna, Austria;

4. Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria

Funder

Sanofi-Aventis GmbH, Austria

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2018.1556668

Reference37 articles.

1. Kanavos P, Tinelli M, Efthymiadou O, et al. London School of Economics. Towards Better Outcomes in Multiple Sclerosis by Addressing Policy Change: The International MultiPLE Sclerosis Study (IMPrESS). March 2018. Available from: http://eprints.lse.ac.uk/66219/1/Kanavos_IMPRESS-Report-March-2016.pdf

2. New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria

3. Baumhackl U. Multiple Sklerose, Prävalenz und Therapie im 12-Jahres Vergleich in Österreich. Wien: Facultas wuv Universitäts; 2014.

4. Epidemiology of Multiple Sclerosis in Austria

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term follow up of alemtuzumab-treated patients: a retrospective study in a Belgian tertiary care center;Acta Neurologica Belgica;2024-04-15

2. COST-EFFECTIVENESS OF DISEASE-MODIFYING TREATMENTS FOR MULTIPLE SCLEROSIS IN BULGARIA BASED ON EVIDENCE FROM REAL WORLD SETTINGS;FARMACIA;2023-12-28

3. Cost-Effectiveness of Multiple Sclerosis Therapies – A Literature Review;Acta Medica Bulgarica;2022-12-01

4. Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis;BMC Health Services Research;2022-01-28

5. How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review;Neurology and Therapy;2021-07-19